Free Trial

Ocular Therapeutix (OCUL) News Today

Ocular Therapeutix logo
$10.39
-0.14 (-1.33%)
(As of 11/1/2024 ET)
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by Analysts
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating o
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Hits New 12-Month High - Should You Buy?
Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week High - Here's Why
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Sees Large Decrease in Short Interest
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 13,260,000 shares, a decline of 18.1% from the September 30th total of 16,190,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is currently 11.4 days.
Ocular Therapeutix, Inc. stock logo
Assenagon Asset Management S.A. Invests $24.58 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,825,756 shares of the biopharmaceutical company's
Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)
Ocular Therapeutix, Inc. stock logo
SG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL)
SG Americas Securities LLC purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 45,187 shares of the biopharmaceutical company's stock,
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 12-Month High - Should You Buy?
Ocular Therapeutix (NASDAQ:OCUL) Sets New 12-Month High - Here's What Happened
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 4.9% - Still a Buy?
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 4.9% - What's Next?
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $14.00 price target on shares of Ocular Therapeutix in a report on Wednesday.
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Coverage Initiated at Scotiabank
Scotiabank started coverage on shares of Ocular Therapeutix in a research note on Wednesday. They issued a "sector outperform" rating for the company.
Ocular Therapeutix, Inc. stock logo
Amendment to 2019 Inducement Stock Incentive Plan Boosts Ocular Therapeutix’s Shares
Ocular Therapeutix, Inc. made a significant change to its 2019 Inducement Stock Incentive Plan, as disclosed in a recent filing with the Securities and Exchange Commission on October 4, 2024. The company's board of directors approved an amendment to increase the total number of shares available unde
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy
Ocular Therapeutix, Inc. stock logo
Marshall Wace LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Marshall Wace LLP purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 429,592 shares of the biopharmaceutical company's stock, valued a
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler
Ocular Therapeutix, Inc. stock logo
Nantahala Capital Management LLC Buys Shares of 1,000,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Nantahala Capital Management LLC purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,000,000 shares of the biopharmaceutical company's stock, valued a
Ocular Therapeutix, Inc. stock logo
Point72 Asset Management L.P. Purchases Shares of 2,706,663 Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Point72 Asset Management L.P. purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,706,663 shar
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Logos Global Management LP
Logos Global Management LP decreased its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 11.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,150,000 shares of the biopharmaceutical company's stock after se
Ocular Therapeutix, Inc. stock logo
Tri Locum Partners LP Makes New $3.52 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Tri Locum Partners LP purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 514,642 shares o
Ocular Therapeutix, Inc. stock logo
Rhumbline Advisers Raises Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Rhumbline Advisers lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 39.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 211,301 shares of the biopharmaceutica
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
TD Cowen Remains a Buy on Lantheus (LNTH)
Ocular Therapeutix, Inc. stock logo
Bank of New York Mellon Corp Buys 164,383 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Bank of New York Mellon Corp grew its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 49.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 495,635 shares of the biopharmaceutical company's stock
Ocular Therapeutix, Inc. stock logo
Aptus Capital Advisors LLC Invests $1.80 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Aptus Capital Advisors LLC purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 262,810 shares of the biopharmace
OCUL Jan 2025 2.500 call
Ocular Therapeutix, Inc. stock logo
Banco Santander S.A. Has $2.58 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Banco Santander S.A. lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 81.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 377,368 shares of the biopharmaceutical company's stock aft
Ocular Therapeutix, Inc. stock logo
Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 1,832 Shares of Stock
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 1,832 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $9.02, for a total transaction of $16,524.64. Following the completion of the transaction, the insider now directly owns 176,194 shares of the company's stock, valued at $1,589,269.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Trading 4.6% Higher
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 4.6%
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Brokerages
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating t
OCUL Sep 2024 17.500 call
Ocular Therapeutix, Inc. stock logo
Deltec Asset Management LLC Buys 226,181 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Deltec Asset Management LLC increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 9.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,590,265 shares of the biopharm
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 4%
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 4%
Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

OCUL Media Mentions By Week

OCUL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OCUL
News Sentiment

0.78

0.42

Average
Medical
News Sentiment

OCUL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OCUL Articles
This Week

3

4

OCUL Articles
Average Week

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners